EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Asundexian Versus Apixaban in Patients With Atrial Fibrillation

Zara Saeed, Syeda Ariba Zehra, Sumyya Tariq, Rocio Pun Zumaran, Mounika Kotte, Zeeshan Hameed, Neeraj Joshi, Pushpa Kumari, Kanta Kumari, Awais Habib, Fawad Talat, Osama Taj und 2 weitere

Health Science Reports · 2026-03 · 9 (3)

DOI: 10.1002/hsr2.71795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Science Reports, online erschienen am 16.03.2026. Verfasst von Zara Saeed und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Ibn e Seena Hospital Kabul Afghanistan. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anticoagulation therapy is central to the prevention of thromboembolic disorders but is limited by bleeding complications associated with traditional agents such as warfarin and direct oral anticoagulants (DOACs). Factor XIa inhibition has emerged as a novel strategy aimed at reducing thrombotic risk while preserving hemostasis. Asundexian, a selective Factor XIa inhibitor, represents a promising advancement in this evolving therapeutic landscape.

Methods

This narrative review synthesizes available preclinical and clinical evidence on Asundexian, with a focus on its pharmacological mechanism, efficacy, safety profile, and potential clinical applications. Key data from major clinical trials, including PACIFIC‐AF and PACIFIC‐STROKE, were reviewed to evaluate its role in contemporary anticoagulation therapy.

Results

Clinical trial evidence indicates that Asundexian effectively reduces the incidence of stroke and systemic embolism in patients with atrial fibrillation and those at risk of recurrent ischemic stroke. Importantly, these benefits are achieved with a lower risk of major bleeding compared to conventional anticoagulants. Asundexian's fixed dosing regimen, oral administration, and lack of routine coagulation monitoring enhance treatment convenience and patient adherence. Emerging data also suggest potential applicability in other conditions requiring long‐term anticoagulation, such as venous thromboembolism and acute coronary syndrome.

Conclusion

Asundexian offers a novel and potentially safer approach to anticoagulation by selectively targeting Factor XIa, balancing thromboembolic protection with reduced bleeding risk. While early clinical results are encouraging, further large‐scale and long‐term studies are required to establish its safety and efficacy across diverse patient populations. Asundexian has the potential to redefine standards of care in anticoagulation therapy and improve patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

Factor XIa inhibitoranticoagulationasundexianbleeding riskthromboembolic prevention

Autor:innen und Institutionen

  • Department of Medicine Ibn e Seena Hospital Kabul Afghanistan.
  • Fauji Foundation Hospital Pakistan.
  • Universidad Autonoma de Guadalajara Mexico.

ORCID-Profile: Jahanzeb Malik, Abida Perveen

Zitieren

APA

Saeed, Z., Zehra, S. A., Tariq, S., Zumaran, R. P., Kotte, M., Hameed, Z., Joshi, N., Kumari, P., Kumari, K., Habib, A., Talat, F., Taj, O., Malik, J., & Perveen, A. (2026). Asundexian Versus Apixaban in Patients With Atrial Fibrillation. Health Science Reports, 9(3). https://doi.org/10.1002/hsr2.71795

Vancouver

Saeed Z, Zehra SA, Tariq S, Zumaran RP, Kotte M, Hameed Z, et al. Asundexian Versus Apixaban in Patients With Atrial Fibrillation. Health Science Reports. 2026;9(3). doi:10.1002/hsr2.71795

BibTeX
@article{Saeed2026,
  author = {Saeed, Zara and Zehra, Syeda Ariba and Tariq, Sumyya and Zumaran, Rocio Pun and Kotte, Mounika and Hameed, Zeeshan and Joshi, Neeraj and Kumari, Pushpa and Kumari, Kanta and Habib, Awais and Talat, Fawad and Taj, Osama and Malik, Jahanzeb and Perveen, Abida},
  title = {Asundexian Versus Apixaban in Patients With Atrial Fibrillation},
  journal = {Health Science Reports},
  year = {2026},
  volume = {9},
  number = {3},
  doi = {10.1002/hsr2.71795}
}
Kostenlos starten →